Date: September 24, 2026
Time: 11-12pm EDT / 5-6pm CEST
Title: Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies
Description:
Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety and efficacy of these therapies can be impacted by immune responses triggered by different molecular components of these drugs (ASO, siRNA, and non-vaccine mRNA/LNP). This webinar will cover recommendations on conducting immunogenicity risk assessments and developing the right monitoring strategies to get these therapies safely to patients.
Speaker:
Title: Immunogenicity Risk Assessment for Nucleic Acid Therapeutics
Description:
Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety and efficacy of these therapies can be impacted by immune responses triggered by different molecular components of these drugs (ASO, siRNA, and non-vaccine mRNA/LNP). This webinar will cover recommendations on conducting immunogenicity risk assessments and developing the right monitoring strategies to get these therapies safely to patients.
